#USA #Denver #Seal Rock #biliary atresia #SRT-015

Seal Rock Therapeutics to Showcase SRT-015 Findings

Seal Rock Therapeutics, a clinical-stage biotech firm, has revealed exciting preclinical findings related to SRT-015, an innovative treatment targeting biliary atresia, a rare and dangerous pediatric liver ailment. The presentation is slated for The Liver Meeting® 2026 held in Denver, Colorado from November 5-9. This year's meeting, hosted by the American Association for the Study of Liver Diseases (AASLD), will serve as a pivotal platform for the latest advancements in liver disease research.

Overview of the Research

In a series of preclinical studies, researchers demonstrated that treatment with SRT-015 led to remarkable results in a neonatal mouse model of biliary atresia. All subjects treated with SRT-015 exhibited 100% survival, a sharp contrast to only 12% survival in control subjects receiving a vehicle treatment. Importantly, 100% of the treated mice maintained sustained bile flow, whereas none in the control group showed this benefit.

Dr. Pranavkumar Shivakumar from the University of Texas Southwestern Medical Center led the research, collaborating with Seal Rock Therapeutics in this ambitious exploration of SRT-015's potential therapeutic impact. The results underscore how the ASK1 inhibitor not only preserved bile flow but also mitigated inflammation and damage to the liver, factors critical to the progression of biliary atresia.

The Significance of Biliary Atresia

Biliary atresia is characterized by the obstruction of bile ducts leading to life-threatening liver damage and a significant unmet need in pediatric healthcare. Currently, no approved drug therapies exist to prevent disease progression post-surgery, with many afflicted children ultimately requiring liver transplants. These recent findings are critical as they provide a compelling case for the development of SRT-015 as a potential solution to this dire medical challenge.

Kathleen Elias, PhD, Vice President of Research and Translational Medicine at Seal Rock Therapeutics, emphasized the importance of these findings, stating, "Our research supports the urgent need for clinical advancement of SRT-015 in addressing biliary atresia given the lack of existing therapies."

Presentation Highlights

The presentation will feature:

• - Oral Presentation: _A phase 2-ready ASK1 inhibitor suppresses post-obstructive cholestatic inflammation and fibrosis in experimental biliary atresia._

- Presenter: Pranavkumar Shivakumar, PhD, FAASLD
- Date/Time: Saturday, November 7, 2026, 2:00 - 2:15 PM MT

• - Poster Presentation: _Preclinical efficacy of a phase 2-ready ASK1 inhibitor, SRT-015, to treat biliary atresia._

- Presenter: Reena Mourya, University of Texas Southwestern Medical Center and Children's Medical Center
- Date/Time: Friday, November 6, 2026, 1:00 - 2:00 PM MT

Looking Ahead

Seal Rock Therapeutics remains committed to exploring SRT-015 as a first-in-class therapy for biliary atresia, aligning with their broader mission to combat severe diseases that currently lack effective treatment options. They are also advancing other promising candidates, including brain-penetrant dual ASK1-LRRK2 inhibitors aimed at treating neurodegenerative disorders such as Parkinson's and ALS.

As the medical community eagerly anticipates these presentations, the hope is that SRT-015 may eventually lead to better outcomes for children suffering from biliary atresia, addressing an urgent need in pediatric liver disease management.

For further details about their research and ongoing projects, Seal Rock Therapeutics can be found at www.sealrocktx.com.